• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603669.SS
Share

Lionco Pharmaceutical Group Co.,Ltd. Stocks

CN¥ 5.91Last Updated 20.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 690.72M

CN¥ 5.91
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Lionco Pharmaceutical Group Co., Ltd., in collaboration with its various subsidiaries, actively participates in the entire lifecycle of pharmaceutical products within China, from initial research and development to manufacturing and sales. The company boasts a comprehensive portfolio of therapeutic solutions, encompassing medications for nutritional support, antimicrobial and antiviral treatments, digestive disorders, cardiovascular health, detoxification, and anti-tumor therapies, alongside other specialized products. Furthermore, it maintains dedicated research institutes that focus specifically on the advancement of chemical, natural, and biological drugs. Established in 2003, Lionco Pharmaceutical Group Co., Ltd. is headquartered in Shannan, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.07.2026 14:04

Nebius shares surged after the disclosure of the size of Nvidia's stake

21.07.2026 13:40

Dalio warns that the bubble may be nearing its peak. What advice does he give investors?

21.07.2026 12:41

Revolut Has Received a License in Australia: It Will Challenge the "Big Four" Banks

21.07.2026 11:49

The CEO of JPMorgan wouldn't go long on bonds or rush into the S&P 500. What is he looking at?

21.07.2026 10:21

Morning Roundup: Oil Is Driving the Market, Revolut’s New License, and Chinese Chips

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026